Salofalk en es it fr

Salofalk Brand names, Salofalk Analogs

Salofalk Brand Names Mixture

  • No information avaliable

Salofalk Chemical_Formula

C6H11NO3

Salofalk RX_link

No information avaliable

Salofalk fda sheet

Salofalk FDA

Salofalk msds (material safety sheet)

Salofalk Synthesis Reference

No information avaliable

Salofalk Molecular Weight

145.156 g/mol

Salofalk Melting Point

No information avaliable

Salofalk H2O Solubility

Freely soluble

Salofalk State

Solid

Salofalk LogP

-1.026

Salofalk Dosage Forms

Cream for topical administration (160 mg/g of methyl aminolevulinate equivalent to 16.0% of methyl aminolevulinate)

Salofalk Indication

For topical use, in combination with 570 to 670 nm wavelength red light illumination, in the treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette).

Salofalk Pharmacology

After topical application of methyl aminolevulinate, porphyrins will accumulate intracellularly in the treated skin lesions. The intracellular porphyrins (including PpIX) are photoactive, fluorescing compounds and, upon light activation in the presence of oxygen, singlet oxygen is formed which causes damage to cellular compartments, in particular the mitochondria. Light activation of accumulated porphyrins leads to a photochemical reaction and thereby phototoxicity to the light-exposed target cells.

Salofalk Absorption

In vitro, after 24 hours the mean cumulative absorption through human skin was 0.26% of the administered dose.

Salofalk side effects and Toxicity

The severity of local phototoxic reactions such as erythema, pain and burning sensation may increase in case of prolonged application time or very high light intensity.

Salofalk Patient Information

Salofalk Organisms Affected

Humans and other mammals